A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.tps1120
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.

Reena S. Cecchini, Peter Y. Chen, Kimberly R. Gergelis, Hyejoo Kang et al.
Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
article

A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.

Reena S. Cecchini, Peter Y. Chen, Kimberly R. Gergelis, Hyejoo Kang, Eileen P. Connolly, Lior Z. Braunstein, Kelly L. Bolton, Erica Stringer-Reasor, Julia R. White, William M. Sikov, Atif J. Khan, Norman Wolmark, Hanna Bandos, Reshma Jagsi, Eleftherios P. Mamounas, Thomas B. Julian, Melissa P. Mitchell, Patricia A. Ganz, Shannon L. Puhalla
article en

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 43(16_suppl)
Allegheny Health Network (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), University of Pittsburgh (US), Loyola University Chicago (US), Washington University in St. Louis (US), Brown University (US), Beaumont Health (US), Columbia University Irving Medical Center (US), UCLA Health (US), University of Rochester Medical Center (US), University of Alabama at Birmingham (US), Florida Hospital Cancer Institute (US), The University of Kansas Cancer Center (US), UPMC Hillman Cancer Center (US), University of Kansas Medical Center (US), Women & Infants Hospital of Rhode Island (US), NRG Oncology (US), NSABP Foundation (US), UCLA Jonsson Comprehensive Cancer Center
Openalex Percentile: Top 80%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.